| July 29th, 2019
We speak to Hank Greely, a Stanford law professor about what you should know when sharing your genetic data with testing companies, plus whether big pharma has a moral obligation to share research findings with the public after a promising discovery.
If you find our articles and interviews helpful, please consider becoming a supporting member of our community.
Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient.
We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.
Please help support our mission.
Henry T. (Hank) Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor, by courtesy, of Genetics at Stanford University. He specializes in ethical, legal and social issues arising from advances in the biosciences, particularly from genetics, neuroscience and human stem cell research. He is President of the International Neuroethics Society; directs the Stanford Center for Law and the Biosciences and the Stanford Program on Neuroscience in Society; chairs the California Advisory Committee on Human Stem Cell Research; and serves on the Committee on Science, Technology and Law of the National Academy of Sciences; the National Academies’ Committee on Developing a Research Agenda and Research Governance Approaches for Climate Intervention Strategies that Reflect Sunlight to Cool Earth; and the NIH BRAIN Initiative’s Multi-Council Working Group, whose Neuroethics Division he co-chairs. He published The End of Sex and the Future of Human Reproduction in May 2016.